I TUOI DATI
I TUOI ORDINI
N. prodotti: 0
Totale ordine: € 0,00
I TUOI ABBONAMENTI
I TUOI ARTICOLI
THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
Rivista di Medicina Nucleare e Imaging Molecolare
A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,413
The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2015 Sep 01
Diagnostic performances of [18f]fluorocholine positron emission tomography in brain tumors
Sollini M. 1, Sghedoni R. 2, Erba P. A. 3, Cavuto S. 4, Froio A. 1, De Berti G. 5, Pisanello A. 6, Fraternali A. 1, Iori M. 1, Iaccarino C. 7, 8, Iori M. 2, Asti M. 1, Filice A. 1, Versari A. 1 ✉
1 Nuclear Medicine Unit, Santa Maria Nuova Hospital - IRCCS Reggio Emilia, Reggio Emilia, Italy;
2 Medical Physics Unit, Santa Maria Nuova Hospital - IRCCS Reggio Emilia, Reggio Emilia, Italy;
3 Regional Center of Nuclear Medicine, University of Pisa, Pisa, Italy;
4 Infrastructure Research and Statistics Unit, Santa Maria Nuova Hospital - IRCCS Reggio Emilia, Reggio Emilia, Italy;
5 Neuroradiology Unit, Santa Maria Nuova Hospital - IRCCS Reggio Emilia, Reggio Emilia, Italy;
6 Neurology Unit, Santa Maria Nuova Hospital - IRCCS Reggio Emilia, Reggio Emilia, Italy;
7 Neurosurgery-Neurotraumatology Unit, University Hospital of Parma, Parma, Italy;
8 Emergency Neurosurgery Unit, Santa Maria Nuova Hospital - IRCCS Reggio Emilia, Reggio Emilia, Italy
AIM: Brain tumors characterization by molecular imaging that allow the depiction of brain lesions metabolic pattern is crucial. Our study aimed: (1) to evaluate the diagnostic performances of [18F]fluoroethylcholine positron emission tomography/computed tomography ([18F]FECH PET/CT), and (2) to correlate PET imaging derived parameters of [18F]FECH to survival in brain tumors.
METHODS: from 2009 to 2012, we enrolled 30 patients who underwent [18F]FECH PET/CT. Final diagnosis was established by clinical and radiological follow-up.
RESULTS: final diagnosis was consistent with tumor disease in 27/30 cases. In 3/30 cases tumor disease was ruled out. [18F]FECH PET/CT resulted true positive and negative in 21/30 and 9/30 patients, respectively. Sensitivity, specificity, positive predictive value, negative predictive value and accuracy of [18F]FECH PET/CT were 78%, 100%, 100%, 33%, and 80%, respectively. Mean and maximum standardized uptake value (SUVmean and SUVmax) resulted statistically correlated to histology (pvalue=0.0255 and =0.0222, respectively). Using a SUVmax cut-off of 2.0 or 3.2 we distinguished between low- and high-grade gliomas with a good specificity (70% and 80%, respectively). SUVmax and histology resulted correlated to overall survival and disease related survival at multivariate analysis.
CONCLUSIONS: our results, worthy of further investigations, show (1) high diagnostic performances of [18F]FECH PET/CT, (2) a correlation between PET imaging derived parameters and survival.